Apresentação: Embalagem com 30 cápsulas
Composição: Cada cápsula contém 50 mg de diacereína. Excipientes: Lacto
Indicações: Artrodar® é indicado no tratamento sintomático da osteoartrite (artrose e afecções articulares do tipo degenerativo).
Posologia: Usar uma a duas cápsulas (50 a 100 mg) de Artrodar® ao dia, durante as refeições. Recomenda-se a dose de uma cápsula (50 mg) por dia, nas primeiras 2 semanas de tratamento. Após esse período, usar 1 cápsula duas vezes ao dia, durante período não inferior a 06 (seis) meses. Seus efeitos benéficos manifestam-se de 2 a 4 semanas após início do tratamento, podendo ser necessário, neste período, o emprego de fármacos analgésicos e anti-inflamatórios.
Mecanismo de ação: Artrodar possui propriedades antiosteoartrósicas e, moderadamente, atividades analgésicas e anti-inflamatórias. A reína, metabólito ativo da diacereína, mostrou capacidade de inibir a síntese de citocinas pró-inflamatórias, tais como a interleucina-1 (IL-1), e a síntese de proteases e radicais livres de oxigênio, todos envolvidos no processo de degradação cartilaginosa. Além disso, estudos indicaram que a diacereína estimula a produção de componentes da matriz cartilaginosa (colágeno e proteoglicanos).
Reg. MS: 1.0341.0052.002-2.
> CLIQUE AQUI E ACESSE A MONOGRAFIA COMPLETA DO PRODUTO
Effects of diacerein at the molecular level in the osteoarthritis disease process
Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits
Effects of diacerein on cartilage and subchondral bone in early stages of osteoarthritis in a rabbit model
Effects of rhein on human articular chondrocytes in alginate beads
Mechanisms of action of diacerein, the first inhibitor of interleukin-1 in osteoarthritis
Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha
In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes
Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage
Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes
Anti-interleukin-1effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures
Articular chondrocytes cultured in hypoxia: their response to interleukin-1beta and rhein, the active metabolite of diacerhein
Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1
Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for Diacerein effects in osteoarthritis
Interleukin-1: its role and approach difficulties in osteoarthritis. Results of a pilot study with diacerein in osteoarthritis of the knee
Interleukin-1, cartilage and osteoarthritis
Cytokines and inflammation in cartilage degradation
Molecular mechanisms implicated in the inhibition of collagenase expression by diacerheine
Effect of diacerhein (ART 50) on the matrix synthesis and collagenase secretion by cultured joint chondrocytes in rabbits
Effects of diacerein on biosynthesis activities of chondrocytes in culture
Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis
Effects of diacerhein on granuloma induced cartilage breakdown in the mouse
Effects of diacerhein in an accelerated canine model of osteoarthritis
The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee:
a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period
The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study
Efficacy and safety of diacerein in osteoarthritis of the knee: adouble-blind, placebo-controlled trial. The Diacerein Study Group
Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac controlled trial in China
A Meta-analysis of Controlled Clinical Studies with Diacerein in the Treatment of Osteoarthritis
A systematic meta-analysis of clinical trials with diacerein in osteoarthritis
An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis
The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee
Diacerein proven as effective as celecoxibe in reducing pain and symptoms in knee osteoarthritis patients in a multicentre double-blind randomised study (DISSCO)
Viscosuplementation with hyaluronic acid as an adjuvant to Diacerein in improving pain, stifnessand physical function in primary osteoarthritic knees: a 1 year follow-up observation study
Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip
A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis